Mongraw-Chaffin Morgana, Foster Meredith C, Kalyani Rita R, Vaidya Dhananjay, Burke Gregory L, Woodward Mark, Anderson Cheryl A M
Department of Medicine (M.M.-C.), University of California, San Diego, La Jolla, California; William B. Schwartz Division of Nephrology (M.C.F.), Tufts Medical Center, Boston, Massachusetts; Department of Medicine (R.R.K.), Johns Hopkins University, Baltimore, Maryland; Department of Epidemiology (D.V., M.W., C.A.M.A.), Johns Hopkins University, Baltimore, Maryland; Division of Public Health Sciences (G.L.B.), Wake Forest School of Medicine, Winston-Salem, North Carolina; The George Institute for Global Health (M.W.), University of Oxford, Oxford, United Kingdom; The George Institute for Global Health (M.W.), University of Sydney, Sydney, Australia; Department of Family Medicine and Public Health (C.A.M.A.), University of California, San Diego, La Jolla, California.
J Clin Endocrinol Metab. 2016 Nov;101(11):4117-4124. doi: 10.1210/jc.2016-2460. Epub 2016 Aug 23.
Although the health risks of obesity compared to normal weight have been well studied, the cumulative risk associated with chronic obesity remains unknown. Specifically, debate continues about the importance of recommending weight loss for those with metabolically healthy obesity.
We hypothesized that relatively greater severity and longer duration of obesity are associated with greater incident metabolic syndrome. Design, Setting, Participants, and Measures: Using repeated measures logistic regression with random effects, we investigated the association of time-varying obesity severity and duration with incident metabolic syndrome in 2,748 Multi-Ethnic Study of Atherosclerosis participants with obesity (body mass index ≥30 kg/m) at any visit. Obesity duration was defined as the cumulative number of visits with measured obesity and obesity severity by the World Health Organization levels I-III based on body mass index. Metabolic syndrome was defined using Adult Treatment Panel III criteria modified to exclude waist circumference.
Higher obesity severity (level II odds ratio [OR], 1.32 [95% confidence interval, 1.09-1.60]; level III OR, 1.63 [1.25-2.14] vs level I) and duration (by number of visits: two visits OR, 4.43 [3.54-5.53]; three visits OR, 5.29 [4.21-6.63]; four visits OR, 5.73 [4.52-7.27]; five visits OR, 6.15 [4.19-9.03] vs one visit duration of obesity) were both associated with a higher odds of incident metabolic syndrome.
Both duration and severity of obesity are positively associated with incident metabolic syndrome, suggesting that metabolically healthy obesity is a transient state in the pathway to cardiometabolic disease. Weight loss should be recommended to all individuals with obesity, including those who are currently defined as metabolically healthy.
尽管与正常体重相比,肥胖对健康的风险已得到充分研究,但慢性肥胖相关的累积风险仍不明确。具体而言,对于建议代谢健康型肥胖者减重的重要性,仍存在争议。
我们假设肥胖的相对严重程度越高、持续时间越长,发生代谢综合征的风险就越大。设计、地点、参与者及测量方法:我们采用随机效应重复测量逻辑回归,在2748名动脉粥样硬化多民族研究参与者中,研究了随时间变化的肥胖严重程度和持续时间与代谢综合征发生之间的关联,这些参与者在任何一次就诊时均患有肥胖症(体重指数≥30kg/m²)。肥胖持续时间定义为测量到肥胖的就诊累积次数,肥胖严重程度根据世界卫生组织基于体重指数的I - III级标准划分。代谢综合征采用修改后排除腰围的成人治疗小组III标准进行定义。
较高的肥胖严重程度(II级比值比[OR]为1.32[95%置信区间为1.09 - 1.60];III级OR为1.63[1.25 - 2.14],对比I级)和持续时间(按就诊次数:两次就诊OR为4.43[3.54 - 5.53];三次就诊OR为5.29[4.21 - 6.63];四次就诊OR为5.73[4.52 - 7.27];五次就诊OR为6.15[4.19 - 9.03],对比一次就诊的肥胖持续时间)均与代谢综合征发生的较高几率相关。
肥胖的持续时间和严重程度均与代谢综合征的发生呈正相关,这表明代谢健康型肥胖是通往心脏代谢疾病途径中的一种短暂状态。应建议所有肥胖个体减重,包括目前被定义为代谢健康的个体。